A phase I/II trial of an oral mTOR protein kinase inhibitor (everolimus, RAD001) in combination with an oral EGFR tyrosine kinase inhibitor (erlotinib, Tarceva) in patients with metastatic breast cancer.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Everolimus (Primary) ; Erlotinib
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 10 May 2016 Biomarkers information updated
- 06 Apr 2011 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
- 06 Apr 2011 Status changed from discontinued to completed as reported by ClinicalTrials.gov.